3-butyryl-4-(2-methoxymethylphenylamino)-8-methoxyquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-butyryl-4-(2-methoxymethylphenylamino)-8-methoxyquinoline
• 英文别名: 3-Butyryl-4-(2-methoxymethyl-phenylamino)-8-methoxyquinoline；1-[8-methoxy-4-[2-(methoxymethyl)anilino]quinolin-3-yl]butan-1-one
• 化学式: C₂₂H₂₄N₂O₃
• 分子量: 364.444
• InChiKey: BCKUPNORJPMZGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  丁酰乙酸乙酯 在 乙酸酐 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 二苯醚 为溶剂， 反应 9.0h， 生成 3-butyryl-4-(2-methoxymethylphenylamino)-8-methoxyquinoline
  参考文献：
  名称：

  Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 4. Identification of an Inhibitor with an Intermediate Duration of Action

  摘要：

  3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK&F 96067). In the present study the further structure-activity relationship of this series is developed. Only a limited range of substituents are tolerated on the N-aryl ring or the 6- and 7-positions of the quinoline, and although hydroxylated derivatives were identified possessing markedly greater affinity for the enzyme, none of these proved to have adequate potency after oral dosing. In contrast, the 8-position of the quinoline ring proved suitable for a wide variety of substituents, allowing modification of physicochemical properties while retaining primary activity. This led to the identification of compound 4 (SK&F 97574), which combines good oral potency with a somewhat longer duration of action than 3 (though much shorter than covalent inhibitors such as omeprazole). This compound was selected for further development and evaluation in man.

  DOI：

  10.1021/jm00014a026

文献信息

• Substituted 4-aminoquinoline derivatives as gastric acid secretion
  申请人：Smith Kline & French Laboratories, Ltd.

  公开号：US05082848A1

  公开（公告）日：1992-01-21

  Substituted 4-aminoquinoline derivatives of the formula: ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxyC.sub.1-6 alkyl; C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-6 alkyl, phenyl C.sub.1-6 alkyl, the phenyl groups being optionally substituted; R.sup.2 is hydroxy C.sub.1-6 alkyl, C.sub.1-6 alkoxyC.sub.1-6 alkyl or two adjacent groups R.sup.2 together form a C.sub.1-4 alkylenedioxy group; R.sup.3 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, amino, C.sub.1-6 alkylthio, halogen, cyano, hydroxy, C1-6alkanoyl, or trifluromethyl; R.sup.4 is hydrogen, C.sub.1-6 alkyl, phenyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.1-6 alkanoyl, amino, C.sub.1-6 alkylamino, di- C.sub.1-6 alkyl amino, halogen, or trifluromethyl; n is 1 or 2; q is 0 to 4; m is 1, 2, or 3; and p is 1, 2, 3, or 4 provided that m+p is not greater than 5; or a salt thereof are useful as inhibitors of gastric acid secretion.

  公式为##STR1##的4-氨基喹啉衍生物，其中R.sup.1是氢，C.sub.1-6烷基，C.sub.1-6烷氧基C.sub.1-6烷基；C.sub.3-6环烷基，C.sub.3-6环烷基-C.sub.1-6烷基，苯基C.sub.1-6烷基，苯基可以选择性地被取代；R.sup.2是羟基C.sub.1-6烷基，C.sub.1-6烷氧基C.sub.1-6烷基或者两个相邻的R.sup.2基团一起形成一个C.sub.1-4烷二氧基基团；R.sup.3是氢，C.sub.1-6烷基，C.sub.1-6烷氧基，氨基，C.sub.1-6烷硫基，卤素，氰基，羟基，C1-6烷酰基或三氟甲基；R.sup.4是氢，C.sub.1-6烷基，苯基，C.sub.1-6烷氧基，C.sub.1-6烷硫基，C.sub.1-6烷酰基，氨基，C.sub.1-6烷基氨基，二C.sub.1-6烷基氨基，卤素或三氟甲基；n为1或2；q为0到4；m为1,2或3；p为1,2,3或4，但要求m+p不大于5；或其盐可用作胃酸分泌抑制剂。
• 4-Amino-3-acylquinoline derivatives and their use as inhibitors of gastric secretion
  申请人：SMITHKLINE BECKMAN INTERCREDIT B.V.

  公开号：EP0331357A1

  公开（公告）日：1989-09-06

  Compound of structure (I) in which R¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkoxy-­C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, phenyl, phenylC₁₋₆alkyl, the phenyl groups being optionally substituted; R² is hydroxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, or two adjacent groups R² together form a C₁₋₆alkylenedioxy group; R³ is hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, amino, C₁₋₆alkylthio, halogen, cyano, hydroxy, C₁₋₆alkanoyl or trifluoromethyl; R⁴ is hydrogen, C₁₋₆alkyl, phenyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkanoyl, amino, C₁₋₆alkylamino, di-C₁₋₆alkylamino, halogen, trifluoromethyl or cyano; n is 1 or 2; q is 0 to 4; m is 1, 2 or 3; and p is 1, 2, 3, or 4 provided that m+p is not greater than 5; processes for their preparation intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy as gastric acid secretion inhibitors.

  结构(I)的化合物 其中 R¹ 是氢、C₁₋₆烷基、C₁₋₆烷氧基、C₁₋₆烷氧基-C₁₋₆烷基、C₃₋₆环烷基、C₃₋₆环烷基C₁₋₆烷基、苯基、苯基C₁₋₆烷基，苯基基团可任选被取代；R² 是羟基C₁₋₆烷基、C₁₋₆烷氧基C₁₋₆烷基，或两个相邻基团 R² 共同形成一个 C₁₋₆ 烷二氧基基团；R³ 是氢、C₁₋₆烷基、C₁₋₆烷氧基、氨基、C₁₋₆烷硫基、卤素、氰基、羟基、C₁₋₆烷酰基或三氟甲基；R⁴ 是氢、C₁₋₆烷基、苯基、C₁₋₆烷氧基、C₁₋₆烷硫基、C₁₋₆烷酰基、氨基、C₁₋₆烷氨基、二₁₋₆烷基氨基、卤素、三氟甲基或氰基；n 是 1 或 2；q 是 0 至 4；m 是 1、2 或 3；p为1、2、3或4，条件是m+p不大于5；用于制备它们的中间体的制备工艺、含有它们的药物组合物以及它们作为胃酸分泌抑制剂在治疗中的用途。
• US5082848A
  申请人：——

  公开号：US5082848A

  公开（公告）日：1992-01-21
• Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 4. Identification of an Inhibitor with an Intermediate Duration of Action
  作者：Colin A. Leach、Thomas H. Brown、Robert J. Ife、David J. Keeling、Michael E. Parsons、Colin J. Theobald、Kenneth J. Wiggall

  DOI：10.1021/jm00014a026

  日期：1995.7

  3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK&F 96067). In the present study the further structure-activity relationship of this series is developed. Only a limited range of substituents are tolerated on the N-aryl ring or the 6- and 7-positions of the quinoline, and although hydroxylated derivatives were identified possessing markedly greater affinity for the enzyme, none of these proved to have adequate potency after oral dosing. In contrast, the 8-position of the quinoline ring proved suitable for a wide variety of substituents, allowing modification of physicochemical properties while retaining primary activity. This led to the identification of compound 4 (SK&F 97574), which combines good oral potency with a somewhat longer duration of action than 3 (though much shorter than covalent inhibitors such as omeprazole). This compound was selected for further development and evaluation in man.